NEWS HIGHLIGHTSMedia Articles Related to Brevoxyl Gel (Benzoyl Peroxide)
EMA: Benefits Outweigh VTE Risks With Hormone Drugs for Acne
Source: Medscape Medical News Headlines [2013.05.17]
The EMA has issued a recommendation that the benefits of the hormonal acne treatment Diane and its generics outweigh the risks, provided that several measures are taken to minimize the risk of thromboembolism.
International Approvals
Research Letter Suggests Twitter May Serve As A Good Forum For Communicating Information About Acne
Source: Health News from Medical News Today [2013.05.17]
JAMA Dermatology Study Highlights A research letter by Kamal Jethwani, M.D., M.P.H., of the Center for Connected Health, Boston, and colleagues suggests that clinicians can learn about the perceptions and misconceptions of diseases like acne via Twitter, and communicate reliable medical information on the popular social media platform...
Pediatricians Endorse New Acne Treatment Guidelines
Source: MedicineNet Acne Specialty [2013.05.06]
Title: Pediatricians Endorse New Acne Treatment Guidelines
Category: Health News
Created: 5/6/2013 10:35:00 AM
Last Editorial Review: 5/6/2013 12:00:00 AM
Tx for Pediatric Acne Gets New Guidance (CME/CE)
Source: MedPage Today Dermatology [2013.05.04]
(MedPage Today) -- Typically seen as a teenager's disease, acne also presents in children and infants, and treatments should be age appropriate, according to new recommendations from the American Acne and Rosacea Society.
With Acne, Bacteria Strain on Your Skin May Be Culprit
Source: MedicineNet Acne Specialty [2013.02.28]
Title: With Acne, Bacteria Strain on Your Skin May Be Culprit
Category: Health News
Created: 2/28/2013 10:35:00 AM
Last Editorial Review: 2/28/2013 12:00:00 AM
Published Studies Related to Brevoxyl Gel (Benzoyl Peroxide)
Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel:
efficacy and tolerability of treatment in moderate to severe acne. [2012]
efficacy of acne medications in skin of color... CONCLUSIONS: Acne subjects with Fitzpatrick skin types IV-VI were not found to be
Treatment of moderate to severe acne vulgaris in a Hispanic population: a
post-hoc analysis of efficacy and tolerability of clindamycin phosphate
1.2%/benzoyl peroxide 2.5% gel. [2012]
in Hispanics... CONCLUSIONS: Overall efficacy and tolerability with clindamycin phosphate
Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. [2011.11]
BACKGROUND: Topical therapy with comedolytics and antibiotics are often advocated for mild and moderate severity acne vulgaris. Nadifloxacin, a new fluoroquinolone with anti-Propionibacterium acnes activity and additional anti-inflammatory activity, is approved for use in acne. This randomized controlled assessor blind trial compared the clinical effectiveness and safety of eight weeks therapy of nadifloxacin 1% versus clindamycin 1% as add-on therapy to benzoyl peroxide (2.5%) in mild to moderate grade acne... CONCLUSIONS: Topical nadifloxacin, a new fluoroquinolone is effective, tolerable, and safe for mild o moderate facial acne. Its clinical effectiveness is comparable to clindamycin when used as add-on therapy to benzoyl peroxide.
Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study. [2011.08]
BACKGROUND: Oral antibiotics in association with a topical retinoid with or without benzoyl peroxide (BPO) are the recommended first-line option in the treatment of moderate to severe acne vulgaris. OBJECTIVES: To evaluate the efficacy and safety of oral lymecycline 300 mg with adapalene 0.1%-BPO 2.5% (A/BPO) fixed-dose gel in comparison with oral lymecycline 300 mg with a vehicle gel in subjects with moderate to severe acne vulgaris... CONCLUSION: These results demonstrate the clinical benefit of combining A/BPO with lymecycline in the treatment of moderate to severe acne vulgaris. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists 2011.
A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. [2011.06]
BACKGROUND: Acne vulgaris is a chronic and frequently recurring disease. A fixed-dose adapalene-benzoyl peroxide (adapalene-BPO) gel is an efficacious and safe acne treatment. OBJECTIVES: To assess the long-term effect of adapalene-BPO on relapse prevention among patients with severe acne after successful initial treatments... CONCLUSIONS: Adapalene-BPO not only prevents the occurrence of relapse among patients with severe acne, but also continues to reduce disease symptoms during 6 months. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists.
Clinical Trials Related to Brevoxyl Gel (Benzoyl Peroxide)
Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris [Completed]
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of
treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening
(safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment
evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a
subject should remain the same during the study.
The primary objective is to demonstrate the superiority in efficacy and assess safety of
adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene
topical gel, 0. 1% (adapalene monad); benzoyl peroxide topical gel, 2. 5% (benzoyl peroxide
monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12
weeks.
A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris [Completed]
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of
treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening
(safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment
evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a
subject should remain the same during the study.
The primary objective is to demonstrate the superiority in efficacy and assess safety of
Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene
Topical Gel, 0. 1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2. 5% (Benzoyl Peroxide
Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12
weeks.
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris [Completed]
Efficacy and Tolerance of a Derivative of Salicylic Acid and 5% Benzoyl Peroxide in Facial Acne Vulgaris [Completed]
Acne vulgaris is a frequent inflammatory skin condition involving the pilosebaceous unit and
affecting more than 80% of teenagers. Mild to moderate acne vulgaris is usually treated with
topical agents such as benzoyl peroxide, retinoids and antibiotics. These treatments can be
associated with local tolerance problems and/or antibiotic resistance. Salicylic acid has
been shown to be an effective treatment for acne. LHA is a lipophilic hydroxy acid derivative
of salicylic acid that has comedolytic and antibacterial properties.
The objective of this trial was to compare the efficacy and tolerance of a cream formulation
containing 0. 3% LHA (LHA formulation) to a 5% benzoyl peroxide gel.
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac� Topical Gel in the Treatment of Acne Vulgaris [Recruiting]
The objective of this study is to compare the relative efficacy and safety of the test
formulation Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to
the marketed formulation Duac® Topical Gel (Clindamycin 1%/Benzoyl Peroxide 5%) (Stiefel) in
the treatment of the inflamed lesions of acne vulgaris. Both the test and reference
formulations will also be compared to a placebo formulation to test for superiority.
|
